ASTERA LABS INC SEC Filings

Astera Labs, Inc. (ALAB) reported an insider stock sale by a director on a Form 4. On 11/20/2025, the reporting person sold a total of 2,500 shares of common stock in a series of market transactions at weighted average prices ranging from about $142.09 to $159.11 per share. The filing states these sales occurred automatically under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025, which is designed to allow systematic selling regardless of day-to-day market conditions. After these transactions, the director directly owned 94,851 shares of Astera Labs common stock. No derivative security transactions were reported.

Astera Labs, Inc. (ALAB) reported insider activity by its General Counsel and Secretary via a Form 4. On 11/17/2025, the officer sold several small blocks of common stock to cover tax withholding tied to the vesting and settlement of previously granted restricted stock units. The filing shows sales of 454, 1,051, 1,801 and 1,314 shares at weighted average prices of $146.4164, $145.6894, $144.5341 and $143.5145, respectively, executed through multiple transactions within specified price ranges. After these sales, the reporting person beneficially owned 147,040 shares of Astera Labs common stock in direct ownership. The filing notes that the sales were automatic "sell to cover" transactions mandated by the issuer and do not represent discretionary trades by the insider.

Astera Labs, Inc. (ALAB) reported insider share activity by its Chief Financial Officer on a Form 4. On 11/17/2025, the CFO had several small sales of common stock, including 1,124, 2,609, 4,459 and 3,238 shares, at weighted average prices between $147.0000 and $143.1850 per share. According to the footnotes, these transactions were automatic “sell-to-cover” sales required to satisfy tax withholding tied to the vesting of previously granted restricted stock units, and are described as non-discretionary.

After these sales, the CFO directly beneficially owned 192,297 shares of common stock. In addition, 450,281 shares were held indirectly through the Tate 1997 Living Trust, where the reporting person is a trustee and disclaims full beneficial ownership except for any pecuniary interest.

Astera Labs, Inc. (ALAB) reported insider transactions by its President and COO, who is also a director, on 11/17/2025. The filing shows several same‑day open‑market sales of Common Stock coded as "S", including 4,421 shares at a weighted average price of $146.6536, 21,100 shares at $145.8837, 26,381 shares at $144.8026, 32,385 shares at $143.8385, and 6,172 shares at $143.2526. The footnotes explain these sales were automatic "sell to cover" transactions to satisfy tax withholding obligations upon vesting and settlement of previously granted restricted stock units, and are described as non‑discretionary. After these transactions, the executive is shown as directly holding 1,599,750 Common Stock shares. The report also lists 6,006,213 shares held by "Trust 1", and 695,000 shares each in "Trust 2" and "Trust 3", with the executive disclaiming beneficial ownership except for any pecuniary interest.

Astera Labs, Inc. (ALAB) reported a Form 4 for its Chief Executive Officer, who is also a director. On 11/17/2025, the reporting person executed several market sales of Astera Labs common stock, with individual transactions including 4,421, 21,100, 26,381, 32,385, and 6,172 shares at weighted average prices between $147.33 and $143.19 per share.

The filing explains that these sales were automatically executed to cover tax withholding obligations arising from the vesting and settlement of previously granted restricted stock units, based on an advance “sell to cover” election by the company, and did not represent discretionary trades by the CEO. After these transactions, the CEO reported direct ownership of 2,080,418 shares, plus additional indirect holdings through various trusts, including 4,130,002 shares held by a living trust and several estate planning trusts holding between 450,001 and 700,000 shares each.

Astera Labs, Inc. (ALAB) reported an insider share purchase by its General Counsel and Secretary. On 11/14/2025, the officer acquired 87 shares of common stock at a price of $78.3615 per share. These shares were bought through the company’s 2024 Employee Stock Purchase Plan in transactions described as exempt under Rule 16b-3(d) and Rule 16b-3(c). Following this transaction, the officer now beneficially owns 151,660 shares of Astera Labs common stock in direct ownership.

Astera Labs (ALAB) reported strong Q3 2025 results. Revenue rose to $230.6 million, up 104% year over year, as higher unit shipments and a richer mix of modules and Scorpio products drove growth. Gross margin was 76.2% versus 77.7% a year ago, reflecting product mix. Operating income reached $55.4 million, and an income tax benefit contributed to net income of $91.1 million (diluted EPS $0.50), compared with a loss last year.

For the first nine months, revenue was $581.9 million (up 128%) with net income of $174.2 million. Cash and cash equivalents were $140.4 million and marketable securities were $994.0 million as of September 30, 2025. Q3 revenue was led by Singapore ($95.6 million), China ($77.4 million), and Taiwan ($37.7 million). Non-GAAP results highlighted operating margin of 41.7% and net income of $88.2 million. Shares outstanding were 168,903,616 as of October 31, 2025. Management noted higher headcount and R&D investments, while the One Big Beautiful Bill Act drove a tax benefit that reduced current U.S. cash taxes.

Astera Labs, Inc. (ALAB) reported that it entered into a definitive agreement to acquire aiXscale Photonics GmbH. The company announced the agreement on October 22, 2025 and furnished a related press release as Exhibit 99.1.

The update was provided under Item 8.01 (Other Events) of a Form 8-K. Astera Labs’ common stock trades on the Nasdaq Global Select Market.